Human Molecular Genetics, 2000, Vol. 9, No. 7 1087-1092
© 2000 Oxford University Press
Alleviation of neuronal ganglioside storage does not improve the clinical course of the NiemannPick C disease mouse
Genetics of Development and Disease Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA, 1Department of Pathology and Laboratory Medicine, The University of North Carolina, Chapel Hill, NC 27599, USA, 2Laboratory of Cell Biochemistry and Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA, 3Developmental and Metabolic Neurology Branch, National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, MD 20892, USA and 4INSERM Unit 189, Lyon-Sud School of Medicine, 69921 Oullins, France
NiemannPick disease Type C (NP-C) is a progressive neurodegenerative disorder caused by mutations in the NPC1 gene and characterized by intracellular accumulation of cholesterol and sphingolipids. The major neuronal storage material in NP-C consists of gangliosides and other glycolipids, raising the possibility that the accumulation of these lipids may participate in the neurodegenerative process. To determine if ganglioside accumulation is a crucial factor in neuropathogenesis, we bred NP-C model mice with mice carrying a targeted mutation in GalNAcT, the gene encoding the ß-1-4GalNAc transferase responsible for the synthesis of GM2 and complex gangliosides. Unlike the NP-C model mice, these double mutant mice did not exhibit central nervous system (CNS) accumulation of gangliosides GM2 or of glycolipids GA1 and GA2. Histological analysis revealed that the characteristic neuronal storage pathology of NP-C disease was substantially reduced in the double mutant mice. By contrast, visceral pathology was similar in the NP-C and double mutant mice. Most notably, the clinical phenotype of the double mutant mice, in the absence of CNS ganglioside accumulation and associated neuronal pathology, did not improve. The results demonstrate that complex ganglioside storage, while responsible for much of the neuronal pathology, does not significantly influence the clinical phenotype of the NP-C model.
+ To whom correspondence should be addressed. Tel: +1 301 496 6774; Fax: +1 301 496 9878; Email: proia@nih.gov
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
A. M. Kaufmann and J. P. Krise Niemann-Pick C1 Functions in Regulating Lysosomal Amine Content J. Biol. Chem., September 5, 2008; 283(36): 24584 - 24593. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Li, S. D. Turley, B. Liu, J. J. Repa, and J. M. Dietschy GM2/GD2 and GM3 gangliosides have no effect on cellular cholesterol pools or turnover in normal or NPC1 mice J. Lipid Res., August 1, 2008; 49(8): 1816 - 1828. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Liu, H. Li, J. J. Repa, S. D. Turley, and J. M. Dietschy Genetic variations and treatments that affect the lifespan of the NPC1 mouse J. Lipid Res., March 1, 2008; 49(3): 663 - 669. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Martino, P. Marconi, B. Tancini, D. Dolcetta, M.G. C. De Angelis, P. Montanucci, G. Bregola, K. Sandhoff, C. Bordignon, C. Emiliani, et al. A direct gene transfer strategy via brain internal capsule reverses the biochemical defect in Tay-Sachs disease Hum. Mol. Genet., August 1, 2005; 14(15): 2113 - 2123. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Yu, M. Ko, K. Yanagisawa, and M. Michikawa Neurodegeneration in Heterozygous Niemann-Pick Type C1 (NPC1) Mouse: IMPLICATION OF HETEROZYGOUS NPC1 MUTATIONS BEING A RISK FOR TAUOPATHY J. Biol. Chem., July 22, 2005; 280(29): 27296 - 27302. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Yu, J.-S. Gong, M. Ko, W. S. Garver, K. Yanagisawa, and M. Michikawa Altered Cholesterol Metabolism in Niemann-Pick Type C1 Mouse Brains Affects Mitochondrial Function J. Biol. Chem., March 25, 2005; 280(12): 11731 - 11739. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Li, G. Brown, M. Ailion, S. Lee, and J. H. Thomas NCR-1 and NCR-2, the C. elegans homologs of the human Niemann-Pick type C1 disease protein, function upstream of DAF-9 in the dauer formation pathways Development, November 15, 2004; 131(22): 5741 - 5752. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. t. Vruchte, E. Lloyd-Evans, R. J. Veldman, D. C. A. Neville, R. A. Dwek, F. M. Platt, W. J. van Blitterswijk, and D. J. Sillence Accumulation of Glycosphingolipids in Niemann-Pick C Disease Disrupts Endosomal Transport J. Biol. Chem., June 18, 2004; 279(25): 26167 - 26175. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Sleat, J. A. Wiseman, M. El-Banna, S. M. Price, L. Verot, M. M. Shen, G. S. Tint, M. T. Vanier, S. U. Walkley, and P. Lobel Genetic evidence for nonredundant functional cooperativity between NPC1 and NPC2 in lipid transport PNAS, April 20, 2004; 101(16): 5886 - 5891. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. C. Reid, N. Sakashita, S. Sugii, Y. Ohno-Iwashita, Y. Shimada, W. F. Hickey, and T.-Y. Chang A novel cholesterol stain reveals early neuronal cholesterol accumulation in the Niemann-Pick type C1 mouse brain J. Lipid Res., March 1, 2004; 45(3): 582 - 591. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Malathi, K. Higaki, A. H. Tinkelenberg, D. A. Balderes, D. Almanzar-Paramio, L. J. Wilcox, N. Erdeniz, F. Redican, M. Padamsee, Y. Liu, et al. Mutagenesis of the putative sterol-sensing domain of yeast Niemann Pick C-related protein reveals a primordial role in subcellular sphingolipid distribution J. Cell Biol., February 16, 2004; 164(4): 547 - 556. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. K. Loftus, R. P. Erickson, S. U. Walkley, M. A. Bryant, A. Incao, R. A. Heidenreich, and W. J. Pavan Rescue of neurodegeneration in Niemann-Pick C mice by a prion-promoter-driven Npc1 cDNA transgene Hum. Mol. Genet., November 15, 2002; 11(24): 3107 - 3114. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Liscum, E. Arnio, M. Anthony, A. Howley, S. L. Sturley, and M. Agler Identification of a pharmaceutical compound that partially corrects the Niemann-Pick C phenotype in cultured cells J. Lipid Res., October 1, 2002; 43(10): 1708 - 1717. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Bu, J. Li, P. Davies, and I. Vincent Deregulation of cdk5, Hyperphosphorylation, and Cytoskeletal Pathology in the Niemann-Pick Type C Murine Model J. Neurosci., August 1, 2002; 22(15): 6515 - 6525. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Tifft and R. L. Proia Stemming the tide: glycosphingolipid synthesis inhibitors as therapy for storage diseases Glycobiology, December 1, 2000; 10(12): 1249 - 1258. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Cruz and T.-Y. Chang Fate of Endogenously Synthesized Cholesterol in Niemann-Pick Type C1 Cells J. Biol. Chem., December 22, 2000; 275(52): 41309 - 41316. [Abstract] [Full Text] [PDF] |
||||







